tetano
Editor, Senior Moderator
J Infect Dis. 2016 Jul 20. pii: jiw310. [Epub ahead of print]
[h=1]Priming Vaccination with H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.[/h] Hoft DF[SUP]1[/SUP], Lottenbach K[SUP]1[/SUP], Goll JB[SUP]2[/SUP], Hill H[SUP]2[/SUP], Winokur PL[SUP]3[/SUP], Patel SM[SUP]4[/SUP], Brady RC[SUP]5[/SUP], Chen WH[SUP]6[/SUP], Edwards K[SUP]7[/SUP], Creech CB[SUP]7[/SUP], Frey SE[SUP]1[/SUP], Blevins TP[SUP]1[/SUP], Salomon R[SUP]8[/SUP], Belshe RB[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] H5N1 and other avian influenza strains represent major pandemic threats. Like all influenza A strains, H5N1 viruses evolve rapidly. Innovative immunization strategies are needed to induce cross-protective immunity.
[h=4]METHODS:[/h] Subjects primed with Clade 1 H5 antigen, with or without adjuvant, and H5 na?ve individuals were boosted with Clade 2 H5 antigen. The impact of priming on T cells capable of both proliferation and cytokine production after antigen restimulation was assessed.
[h=4]RESULTS:[/h] Subjects previously vaccinated with Clade 1 H5 antigen developed significantly enhanced Clade 2 H5 cross-reactive T cell responses detectable 6 months post-vaccination with Clade 2 H5 antigen. Priming dose (15 ?g vs. 45 or 90 ?g) had no effect on magnitude of heterotypic H5 T cell responses. In contrast, age at priming negatively modulated both magnitude and duration of heterotypic H5 T cell responses. Elderly subjects developed significantly less heterotypic H5 T cell boosting, predominantly for T cells capable of cytokine production. Adjuvant had a positive albeit weaker effect than age. Magnitude of CD4+ IFN-γ producing T cells correlated with H5 antibody responses.
[h=4]CONCLUSIONS:[/h] H5 heterotypic priming prior to onset of an H5N1 pandemic may increase magnitude and duration of immunity against a newly drifted pandemic H5 virus.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
PMID: 27443611 DOI: 10.1093/infdis/jiw310
[PubMed - as supplied by publisher]
[h=1]Priming Vaccination with H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.[/h] Hoft DF[SUP]1[/SUP], Lottenbach K[SUP]1[/SUP], Goll JB[SUP]2[/SUP], Hill H[SUP]2[/SUP], Winokur PL[SUP]3[/SUP], Patel SM[SUP]4[/SUP], Brady RC[SUP]5[/SUP], Chen WH[SUP]6[/SUP], Edwards K[SUP]7[/SUP], Creech CB[SUP]7[/SUP], Frey SE[SUP]1[/SUP], Blevins TP[SUP]1[/SUP], Salomon R[SUP]8[/SUP], Belshe RB[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] H5N1 and other avian influenza strains represent major pandemic threats. Like all influenza A strains, H5N1 viruses evolve rapidly. Innovative immunization strategies are needed to induce cross-protective immunity.
[h=4]METHODS:[/h] Subjects primed with Clade 1 H5 antigen, with or without adjuvant, and H5 na?ve individuals were boosted with Clade 2 H5 antigen. The impact of priming on T cells capable of both proliferation and cytokine production after antigen restimulation was assessed.
[h=4]RESULTS:[/h] Subjects previously vaccinated with Clade 1 H5 antigen developed significantly enhanced Clade 2 H5 cross-reactive T cell responses detectable 6 months post-vaccination with Clade 2 H5 antigen. Priming dose (15 ?g vs. 45 or 90 ?g) had no effect on magnitude of heterotypic H5 T cell responses. In contrast, age at priming negatively modulated both magnitude and duration of heterotypic H5 T cell responses. Elderly subjects developed significantly less heterotypic H5 T cell boosting, predominantly for T cells capable of cytokine production. Adjuvant had a positive albeit weaker effect than age. Magnitude of CD4+ IFN-γ producing T cells correlated with H5 antibody responses.
[h=4]CONCLUSIONS:[/h] H5 heterotypic priming prior to onset of an H5N1 pandemic may increase magnitude and duration of immunity against a newly drifted pandemic H5 virus.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
PMID: 27443611 DOI: 10.1093/infdis/jiw310
[PubMed - as supplied by publisher]